Taysha Gene Therapies, Inc.
We are a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations. (AAV stands for adeno-associated virus.) Our most advanced product candidates include TSHA-101, which is being developed to treat genetic disorders that include Tay-Sachs disease, […]
September 2, 2020 Read More